The majority of non-Hodgkin's B cell lymphomas (NHL) 
Introduction
For personal use only. on . by guest www.bloodjournal.org Id contains epitopes recognized by antibodies 1, 2, 3 , and epitopes presented to T cells 4 5 2,6-10 . These unique features have led to the development of several strategies for active and passive Id-specific immunotherapy 11, 12 . Initial clinical trials demonstrated that passive transfer of monoclonal Id-specific antibodies can be effective in the treatment of NHL 1 , although tumor escape often limits the efficacy of this approach [13] [14] [15] [16] . Active immunization with tumor-derived Id protein was first shown to be effective in mouse models of lymphoma 2 3,17 , been often emphasized 18, 19 , and infusion of tumor-reactive CD8 + T cells expanded to large numbers in vitro has been effective in eliminating tumors in animal models and cancer patients [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . CD4 + T cells can not only provide critical support for the generation and maintenance of CD8 + responses but also mediate anti-tumor activity 30, 31 . Thus, efforts have been made to boost CD4 + and CD8 + responses to the Id.
Strategies have included fusion of the antigen with xenogeneic constant regions, or fusion of a single-chain Fv (scFv) with molecules to enhance immunogenicity, such as fragment C of tetanus toxoid 32 , cytokines such as GM-CSF, IL-4, IL-2,IL-1β 33 34 35 36 .
Clinical trials produced encouraging immunologic cellular responses that correlated
For personal use only. on . by guest www.bloodjournal.org From with improvement in relapse-free and overall survival. Following administration of Id-KLH conjugates with GM-CSF, Id-specific cellular responses were induced in 15 of 23 patients, and immune responses were associated with molecular remission in the majority of patients 37 . Administration of DCs pulsed with Id induced cellular Idspecific immune responses in 65% of patients 9, 27 . Despite the observed clinical benefit, the efficacy of these vaccines may have been limited in part by the inefficient induction of Id-specific CD8 + T cell responses, presumably as a result of providing the antigen exogenously as a protein. 
Materials and methods

Mice
Six-week old female C3H/HeN (Charles River, Calco, Italy) were housed in a specific pathogen free animal facility, and treated in accordance with the European Union guidelines, and with the approval of the Institutional Ethical Committee.
Cell lines
38C13 is a carcinogen-induced murine B cell lymphoma tumor that expresses IgM/k on its surface and is MHC I + , MHC II -46 47 . All experiments were performed with cells from a cell bank of frozen 38C13 cells. 38C13 cells were maintained in RPMI 1640, 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µM 2-ME (complete medium) at 37°C, 5% CO 2 in a humidified incubator. CH27 is a carcinogen-induced B cell lymphoma tumor that also expresses IgM/k on its surface, but this idiotype is different from the one expressed by 38C13.
CH27 cells were maintained under the same culture conditions as 38C13.
Generation of DCs
DCs were prepared from bone marrow of C3H mice. Briefly, single-cell suspensions of bone marrow were seeded into six-well plates at 2x10 6 /ml in Iscove's Modified Dulbecco's Medium (Cambrex, Belgium) supplemented with penicillin-streptomycin and 10% FCS, GM-CSF (25 ng/ml), and IL-4 (5 ng/ml; BD Canada) for five days.
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Eight hours before harvesting the non-adherent and loosely adherent cells, LPS (1 µg/ml) was added to the culture medium as a maturation signal for DCs.
Antibodies
The purity of DCs was evaluated by cell surface staining with PE-conjugated Abs to CD11c and PE-conjugated isotype controls (BD Biosciences, Belgium). Activation of DCs was evaluated by staining the cells with PE-conjugated Abs to CD80, CD86 and I-A K (BD Biosciences, Belgium) and isotype controls. The samples were analyzed on a FACSCalibur (BD Biosciences, Belgium) using CellQuest software. Data shown are representative of three or more independent experiments.
Plasmids and vaccinia viruses
The Sig-HA1-V L -LAMP1 and Sig-V H -HA1-LAMP1 genes were constructed by 20 cycles of strand overlap extension PCR with the high fidelity PWO DNA polymerase 
Immunofluorescence staining
To verify the intracellular localization of transgene expression, DCs were infected for for 20 min at room temperature, and analyzed by FACScan.
Vaccination protocol
Mice were immunized with 0.3x10 6 syngeneic DCs infected with recombinant vaccinia viruses coding for Id, Id-LAMP1 or S65L as negative control 40 . Cells were injected s.c. in 200 µl of 0.9 % NaCl .
In vitro cytotoxicity against tumor cell lines
Fourteen days after vaccination, animals were sacrificed and spleens and lymph nodes were harvested. Splenocytes were resuspended in complete medium at 2.5x10 6 /ml in T25 flasks with 1x10 6 
Thymidine incorporation assay
Splenocytes were stimulated with 30 cGy irradiated 38C13 or CH27 tumor cells as described above and at a day 4 IL-2 (25 UI/ml) was added. After a total of 8 days of culture, cells were isolated on a Lympholyte-M gradient and CD4 + cells purified by negative selection with anti-CD8 conjugated beads (Miltenyi). To test for proliferation to the idiotype, DCs generated from naïve C3H mice were transfected with mRNA coding for Sig-HA1-V L -LAMP1 and Sig-V H -HA1-LAMP1 or S65L as a control, as previously described 48 . Briefly, 1x10 6 
In vivo depletion of CD4 + and CD8 + T cells
MAbs GK1.5 (rat IgG2b anti-murine CD4) and 53.6.72 (rat IgG2a anti-murine CD8) (Abinova Corporation, Taiwan) were used for in vivo depletion of CD4 + and CD8 + Tcell subsets, respectively. Groups of 6 mice were each injected i.p. with either 300 µl of anti-CD4 (GK1.5) or anti-CD8 (53.6.72), or with both anti-CD4 and anti-CD8 mAbs at day -3, -1, +2 and +5, with day 0 designated as the day of vaccination with DC infected with the different rVVs. Six non-depleted mice were analyzed as controls. At day 14 mice were challenged with 1000 viable 38C13 tumor cells s.c. and followed for survival. On the days of vaccination (day 0) and tumor challenge (day 14), blood samples were collected and analyzed by flow cytometry for CD4 + and CD8 + T cells subsets.
Statistical analysis
Data obtained from DCs maturation experiments were analysed by a two tailed Student's t test (Microsoft, Excel). Survival proportions were analysed by a Fisher's Exact test (GraphPad Prism). The results were considered to be significant when p<0.05.
Results
Activated murine DCs can be infected by vaccinia virus and maintain a mature phenotype after rVV infection
Infection of human immature DC (DCimm) with rVV blocks the ability of DC to mature in response to maturation signals 40, 49 . Since DC maturation is required for stimulation of T cell responses, and since many viral activities that interfere with antigen presentation are species specific, we tested if this blockade also occurred in 1f ) were significantly higher (p<0.05) in rVV infected DCmat (exposed to LPS for 8 h before infection) than in rVV-infected DCimm subsequently exposed to LPS for 8h.
Expressions of I-A k and of CD86 were similar in uninfected DCmat and in DCmat subsequently infected with rVV. Additionally, DCmat were more resistant to the cytopathic effects of rVV than DCimm (data not shown). Since DCs have been reported to be more effective when infused 8 h rather than 48 h after exposure to an activation signal 50 , in vivo experiments were performed with DC after 8 h exposure to LPS followed by rVV infection.
The idiotype can be targeted to the lysosomal/endosomal compartment in DCmat
To target antigen processing into the class II presentation pathway, rVVs coding for (Table 1) 
Immune responses elicited by DCmat infected with rVV-Id and rVV-Id-LAMP1 protect from tumor growth
To determine if the immune responses elicited by this vaccine were able to protect animals from tumor development, groups of 12 mice were vaccinated with DCmat infected with rVV-Id, rVV-Id-LAMP1 and rVV-S65L, as previously described. 64 55 , suggesting that a strong T cell response may significantly improve the treatment of NHL.
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